TAKTakeda Pharmaceutical Company Limited
Is it safe?
Nothing alarming, nothing pristine: insiders quiet, comfortable debt (A), and steady price behavior.
Insiders were net sellers (-$13.1M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Relatively steady, low volatility. Worst drawdown -60% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TAK take a bad year?
Takeda Pharmaceutical Company Limited carries $4.13T of net debt at 3.74× EBITDA: a load its earnings can carry.
Net debt · as at FY2025 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.74×
Net debt / EBITDA · 4.66× a year ago · the load is coming down
- Interest cover
- 2.49×
Interest cover · operating profit covers the interest bill, with room to spare
- Annualised volatility
- 21%
Annualised volatility · about as steady as the market itself
Details›
- Total debtFY2025
- $4.52T
- Cash and short-term investments
- $385.1B
- Net debt
- $4.13T
- EBITDA, trailing twelve months
- $1.10T
- Operating profit, trailing twelve months
- $342.6B
- Debt / equity
- 0.65×
- Total debt / EBITDA
- 4.09×
- Annualised volatilitytwo years of daily moves
- 21%
- Worst drawdown on file
- −60%
- Below its 52-week high
- 1.7%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #15 of 41 by RyuScore